Skip to main content

Stem Cell therapy in IschEmic Non-treatable Cardiac diseasE (SCIENCE)

Objective

Stem Cell therapy in IschEmic Non-treatable Cardiac diseasE (SCIENCE)

With more than 17 million deaths worldwide each year, ischemic heart disease (IHD) caused by coronary artery disease is the most common cause of death and a major cause of hospital admissions in industrialised countries. IHD caused over four million deaths in Europe in the year 2012 constituting 47% of all deaths. Today IHD is the main cause of death among women throughout Europe and the main cause of death among men in all but six European countries.

Conventional therapies have reduced mortality of IHD significantly, but have left an increasing number of patients with chronic IHD and/or heart failure without further treatment options. An increasing morbidity rate of this nature in an ageing population is a huge burden for society.

The overall aim of the SCIENCE project is to implement an effective stem cell-based therapy with allogeneic adipose derived stromal cells to improve myocardial function in patients with ischemic heart disease and heart failure. This goal will be achieved by conducting a multicentre clinical trial in a strong consortium of experienced international scientists and experts as well as significant representatives of the biomedical industry within translational medicine and a close collaboration with relevant authorities.

The consortium will ensure feasibility of treatment by simplifying and rationalising cell production and distribution using state-of-the art manufacturing technology that makes cell therapy a realistic option for clinical practise. The consortium expects the SCIENCE project to pave the way for future approval of this treatment by national authorities throughout Europe as the standard form of care for patients with ischemic heart disease and heart failure.

This concept will establish a new platform for growth and consolidation of innovative small and medium-size companies within stem cell research and development. Such a platform will ease implementati

Field of science

  • /medical and health sciences/medical biotechnology/cells technologies/stem cells
  • /social sciences/sociology/demography/mortality

Call for proposal

H2020-PHC-2014-single-stage
See other projects for this call

Funding Scheme

RIA - Research and Innovation action

Coordinator

REGION HOVEDSTADEN
Address
Kongens Vaenge 2
3400 Hillerod
Denmark
Activity type
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
EU contribution
€ 3 309 862

Participants (8)

SLASKI UNIWERSYTET MEDYCZNY W KATOWICACH
Poland
EU contribution
€ 416 000
Address
Ul. Poniatowskiego 15
40 055 Katowice
Activity type
Higher or Secondary Education Establishments
MEDIZINISCHE UNIVERSITAET WIEN
Austria
EU contribution
€ 321 875
Address
Spitalgasse 23
1090 Wien
Activity type
Higher or Secondary Education Establishments
UNIVERZITETNI KLINICNI CENTER LJUBLJANA
Slovenia
EU contribution
€ 423 125
Address
Zaloska Cesta 002
1000 Ljubljana
Activity type
Higher or Secondary Education Establishments
TERUMO BCT EUROPE NV
Belgium
EU contribution
€ 232 083
Address
Ikaroslaan 41
1930 Zaventem
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
UNIVERSITAIR MEDISCH CENTRUM UTRECHT
Netherlands
EU contribution
€ 670 625
Address
Heidelberglaan 100
3584 CX Utrecht
Activity type
Higher or Secondary Education Establishments
WILLIAM COOK EUROPE ApS
Denmark
EU contribution
€ 57 812
Address
Sandet 6
4632 Bjaeverskov
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
CARDIOLOGICUM HAMBURG
Germany
EU contribution
€ 423 750
Address
Schlossgarten 3
22041 Hamburg
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
KOBENHAVNS UNIVERSITET
Denmark
EU contribution
€ 143 750
Address
Norregade 10
1165 Kobenhavn
Activity type
Higher or Secondary Education Establishments